Stock listing

gettex:0JZ Carvolix Aktie

German listing (gettex) of Carvolix · home listing Euronext:CVX

Follow Carvolix into a list and get an email when it puts out news.

Home listing price · EURONEXT:CVX

€4.29 EUR -0.38 (-8.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, EURONEXT:CVX

Past year +171.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€4.20 – €4.66 EURNov 20, 2026
Volume
47,082 sharesNov 20, 2026
Market cap
€267.0M EURAt the close on Nov 20, 2026 · price × 62.23M shares outstanding
52-week range
€1.33 – €7.56 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€152,430 EURMedian day 15,652 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Carvolix logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:CVX · Home€4.29 EUR-0.38 (-8.1%)47,082€4.30€4.66€4.20€4.67Close on Nov 20, 2026
Frankfurt:0JZ€4.44 EUR-0.13 (-2.8%)—€4.43€4.50€4.43€4.57Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:CVX · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€4.29-0.38-8.1%€4.30€4.66€4.2047,082
€4.67+0.07+1.5%€4.60€4.74€4.606,730
€4.60-0.20-4.2%€4.81€4.81€4.5712,791
€4.80-0.05-1.0%€4.82€4.93€4.7019,415
€4.85-0.09-1.8%€5.10€5.10€4.8512,558
€4.94-0.10-2.0%€5.10€5.10€4.8816,786
€5.040.000.0%€5.04€5.08€4.8535,839
€5.04+0.12+2.4%€4.92€5.24€4.9228,140
€4.92+0.02+0.4%€4.91€5.08€4.8813,903
€4.90-0.05-1.0%€4.92€5.02€4.8423,570
€4.95-0.33-6.3%€5.32€5.34€4.8753,317
€5.28-0.04-0.8%€5.42€5.46€5.268,221
€5.32-0.16-2.9%€5.46€5.50€5.3215,565
€5.48-0.18-3.2%€5.68€5.68€5.4814,055
€5.66-0.10-1.7%€5.78€5.78€5.607,998
€5.76+0.22+4.0%€5.56€5.80€5.4611,525
€5.54+0.02+0.4%€5.60€5.64€5.4813,245
€5.52-0.36-6.1%€5.88€5.90€5.3640,218
€5.88+0.10+1.7%€5.80€6.08€5.7629,181
€5.78-0.16-2.7%€5.94€5.94€5.766,634
€5.94+0.02+0.3%€5.96€5.96€5.7615,136
€5.92+0.16+2.8%€5.78€5.92€5.6624,320
€5.76-0.24-4.0%€5.88€5.88€5.5216,950
€6.00+0.74+14.1%€5.16€6.00€4.9267,293
€5.26+0.10+1.9%€5.20€5.34€5.1214,630
€5.16-0.02-0.4%€5.24€5.24€5.086,643
€5.18-0.04-0.8%€5.22€5.22€5.1411,515
€5.22-0.08-1.5%€5.26€5.26€5.0421,540
€5.30-0.08-1.5%€5.38€5.42€5.2810,832
€5.38+0.12+2.3%€5.58€5.58€5.2811,271
€5.26-0.42-7.4%€5.66€5.72€5.2224,788
€5.68-0.10-1.7%€5.78€5.80€5.609,490
€5.78+0.14+2.5%€5.68€5.80€5.666,521
€5.64-0.14-2.4%€5.80€5.80€5.5611,912
€5.78+0.04+0.7%€5.76€5.86€5.7031,127
€5.74-0.04-0.7%€5.80€5.86€5.7028,114
€5.78+0.24+4.3%€5.74€5.82€5.5420,707
€5.54+0.02+0.4%€5.52€5.80€5.4822,070
€5.52-0.12-2.1%€5.68€5.68€5.4812,884
€5.64-0.06-1.1%€5.76€5.76€5.608,195
€5.70-0.12-2.1%€5.84€5.84€5.709,644
€5.82+0.16+2.8%€5.82€5.92€5.7630,555
€5.66-0.04-0.7%€5.70€5.70€5.6013,344
€5.700.000.0%€5.74€5.76€5.6412,976
€5.70-0.08-1.4%€5.88€5.88€5.707,537
€5.78-0.10-1.7%€5.90€5.90€5.749,730
€5.88+0.08+1.4%€5.80€5.90€5.785,504
€5.80-0.06-1.0%€5.88€5.88€5.7215,739
€5.86-0.02-0.3%€5.90€5.96€5.849,965
€5.88+0.02+0.3%€5.96€5.96€5.827,495
€5.86+0.22+3.9%€6.00€6.16€5.8233,285
€5.64-0.16-2.8%€5.78€5.80€5.5235,964
€5.80+0.10+1.8%€5.76€5.86€5.7612,475
€5.700.000.0%€5.70€5.70€5.7021,816
€5.70-0.42-6.9%€6.26€6.26€5.6691,388
€6.12+0.16+2.7%€6.04€6.16€5.9611,968
€5.96-0.22-3.6%€6.18€6.20€5.9419,749
€6.18-0.10-1.6%€6.28€6.44€6.1630,698
€6.28-0.12-1.9%€6.40€6.48€6.2217,244
€6.40-0.18-2.7%€6.58€6.60€6.3241,217
€6.58+0.08+1.2%€6.52€6.72€6.4428,953
€6.50-0.68-9.5%€7.08€7.10€6.50107,906
€7.18+1.06+17.3%€6.66€7.32€6.44274,972
€6.12+0.06+1.0%€6.06€6.22€6.0229,922
€6.06+0.04+0.7%€6.12€6.28€6.0211,152
€6.02-0.12-2.0%€6.10€6.22€6.0020,188
Ticker
gettex:0JZ
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
gettex
Currency
EUR

What changed lately

Latest news

All Carvolix news

Carvolix on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
19 in the last 12 months · 19 in all · newest Nov 4, 2026 · oldest 2025
Decks
3 decks · latest Sep 16, 2026

Where Carvolix is listed

ListingExchangeCountryCurrency
Euronext:CVX · Home listingEuronextFranceEUR
gettex:0JZ · This pagegettexGermanyEUR
LS Exchange:A3CRZTLS ExchangeGermanyEUR
Lang & Schwarz:A3CRZTLang & SchwarzGermanyEUR
Aquis:CVXPAquisUnited KingdomEUR
Aquis:CVXPAquisUnited KingdomEUR
Frankfurt:0JZFrankfurtGermanyEUR
Munich:0JZMunichGermanyEUR
Stuttgart:0JZStuttgartGermanyEUR

Valuation

Price/book 6.2× against a median of 3.3×: 8th lowest of 11 Medical devices & supplies companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
€279.4M EUR
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
6.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.5×
Beta
No index for this market yet

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Carvolix · EURONEXT:CVXUS$293.0MUS$306.6Mn/an/an/a6.2×n/a0.5×n/a
CapsoVision, Inc. · NASDAQ:CVUS$325.1MUS$304.1Mn/a21.9×n/a12.3×−210.1%0.0×0.88
NIOX Group PLC · LSE:NIOXUS$318.1MUS$297.0M34.7×4.7×15.3×3.7×14.4%0.0×n/a
Nanjing Medlander Medical Technology Co. Ltd. Class A · SSE:688273US$315.5MUS$208.7M33.0×3.6×n/a1.5×16.6%0.0×n/a
Supermax Corp. Bhd. · MYX:SUPERMXUS$312.4MUS$215.6Mn/a1.2×n/a0.3×−20.9%0.1×n/a
Chongqing Xishan Science and Technology Co., Ltd. Class A · SSE:688576US$301.5MUS$216.0Mn/a5.2×n/a1.2×−19.2%0.0×n/a
Sanara MedTech Inc. · NASDAQ:SMTIUS$299.1MUS$329.0Mn/a2.9×34.4×39.0×−2.7%6.1×0.49
Peijia Medical Ltd. · HKEX:9996US$297.8MUS$280.7Mn/a2.6×n/a1.1×−28.5%0.3×n/a
Jiangsu Apon Medical Technology Co. Ltd. Class A · SZSE:300753US$293.3MUS$281.1Mn/a5.8×n/a3.0×−9.1%0.0×n/a
Treace Medical Concepts, Inc. · NASDAQ:TMCIUS$282.6MUS$302.8Mn/a1.5×n/a4.6×−27.4%1.0×2.03
NeuroPace, Inc. · NASDAQ:NPCEUS$273.9MUS$283.8Mn/a2.8×n/a23.8×−18.4%5.2×1.23
Median of the othersUS$300.3MUS$282.4M33.9×3.3×24.9×3.3×−18.8%0.1×1.06

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
8.78 EUR · Analysts' mean
EPS, year to Dec 2026
-0.48 · 2 analysts
Revenue, year to Dec 2026
1.43M · 4 analysts

Team and board

DirectorRole
Anne LangeChair of the Board of Directors
Michel TherinVice-Chair of the Board
Rute FernandesDirector

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck23 slidesSep 16, 2026
Affluent Medical — IPO Roadshow (May 2021)IPO roadshow49 slidesMay 27, 2021
Affluent Medical — IPO Roadshow (May 2021)IPO roadshow49 slidesMay 2021

Open Decks

Financings

RaiseDateIn US dollars
Senior secured convertible bonds, amortised bonds and warrants
Announced: up to €30M · Warrants at €3.96 for 120 months
Buyers: Claret Capital Partners (lender; first tranche of EUR 10,000,000 convertible bonds drawn, up to EUR 30 million in total, plus 290,937 warrants issued to CEGCF IV Aggregator L.P. (a Claret entity))
Use of proceeds: US commercialization of the TAVIPILOT Robotic System and development of Kalios, Artus, Artedrone and Mitrapilot
Aug 6, 2026US$34.59M
Private placement of new ordinary shares
Announced: €10M · €3.36 a share
Buyers: Edwards Lifesciences (EUR 5 million (1,488,095 New Shares)); funds managed by Truffle Capital (EUR 5 million (1,488,095 New Shares))
Insiders: Funds managed by Truffle Capital subscribed EUR 5 million; directors affiliated with Truffle Capital did not participate in the board deliberations
Use of proceeds: Product development (Tavipilot, Kalios, Artus, Artedrone, Mitrapilot) and EUR 2.5 million to repay a Truffle Capital bridge financing
Jun 24, 2026US$11.35M
Private placement of new ordinary shares
Tranche closed: €10.3M raised · €2.34 a share
Buyers: Edwards Lifesciences (2,136,752 new shares; 9.7% ownership post-round); Truffle Medeor FPCI (€1.5M in the first tranche at €2.34 per share); Truffle BioMedTech Crossover FPCI (€3.5M in the first tranche at €2.34 per share); Truffle BioMedTech Crossover; Truffle Innov FRR; Truffle Medeor; Financière Memnon; HAYK Holding Sàrl; Ginko Invest; Simone Merkle; Edwards Lifesciences Holding, Inc.; Truffle Capital (funds managed by Truffle Capital; 2,136,751 new shares)
Insiders: Truffle Capital funds (related party; Dr. Philippe Pouletty, Truffle representative and director, abstained) commit €1.5M and €3.5M in the first tranche
Use of proceeds: Extend cash runway to end of May 2026; clinical and regulatory development of TAVIpilot, Artus, Kalios, Epygon and ARTE-DRONE
Feb 2, 2026US$12.15M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue04.12M0000
Cost of revenue13.4M2.42M2.44M2.74M
Gross profit-9.27M-1.20M-1.10M-1.29M
Research and development94.0K72.0K52.0K23.0K
Selling, general and administrative13.7M11.8M5.16M5.19M
Operating income-23.7M-14.6M-15.4M-14.3M-13.2M-13.0M
Depreciation and amortization6.63M2.40M2.41M2.45M2.42M1.91M
EBITDA-17.1M-12.2M-13.0M-11.8M-10.8M-11.1M
Interest expense242.0K393.0K1.08M3.06M
Income before tax-25.1M-14.9M-15.8M-15.4M-15.3M-14.5M
Income tax-123.0K-142.0K-150.0K-173.0K-437.0K-209.0K
Net income-25.0M-14.7M-15.7M-15.2M-14.8M-14.3M
Earnings per share, basic-0.63-0.41-0.54-0.81-0.88-1.07
Earnings per share, diluted-0.63-0.41-0.54-0.81-0.88-1.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents1.75M1.23M1.66M2.58M11.4M5.65M
Short-term investments5.39M
Receivables3.45M3.40M4.05M2.89M
Current assets7.10M12.2M5.79M7.18M14.7M7.91M
Goodwill26.8M32.2M32.2M32.2M32.2M32.2M
Total assets48.0M60.9M56.7M60.0M70.0M64.8M
Accounts payable6.08M4.73M3.37M3.02M1.79M2.35M
Current liabilities23.5M9.53M8.42M8.64M7.30M9.77M
Long-term debt11.9M14.1M14.4M14.9M16.1M16.2M
Total debt22.9M15.5M16.2M16.6M18.5M19.8M
Total liabilities30.6M25.2M26.2M26.5M
Shareholders' equity5.76M30.3M31.5M33.8M43.5M35.3M
Shares outstanding39.3M39.3M30.9M20.8M18.2M15.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-11.6M-11.3M-12.1M-11.1M-12.4M-8.94M
Capital spending-116.0K-147.0K-171.0K-146.0K-334.0K-304.0K
Free cash flow-11.7M-11.5M-12.2M-11.2M-12.7M-9.24M
Cash from investing5.25M-480.0K-184.0K-146.0K-160.0K-304.0K
Cash from financing6.83M11.4M11.3M2.40M18.3M12.8M
Change in cash524.0K-434.0K-922.0K-8.83M5.76M3.52M

Open Financials

Filings

Open Filings

Cap table

Built by 6ix from Carvolix’s releases · as of Aug 6, 2026

Common shares
62,228,152
Fully diluted
62,228,152

Fully diluted

LineShares
Common shares62,228,152

Share count over time

CountShares
Nov 22, 202662,228,152

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Holding Incubatrice Serie I
Membre du Conseil d'Administration
Buy1,868EUR 5.35EUR 9,994Oct 26, 2026
Holding Incubatrice Serie I
Philippe POULETTY, Directeur Général Truffle Capital
Buy1,868EUR 5.35EUR 9,994Oct 26, 2026
Holding Incubatrice Serie I
Membre du Conseil d'Administration
Buy7,470EUR 5.35EUR 39,965Oct 19, 2026
Holding Incubatrice Serie I
Membre du Conseil d'Administration
Buy11,206EUR 5.35EUR 59,952Oct 5, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anne LangeChair of the Board of Directors · Since Apr 9, 2026
Liane TeplitskyChair of the Board of Directors of Carvolix, , · Since at least Apr 9, 2026
Michel TherinVice-Chair of the Board · Since Apr 9, 2026
Rute FernandesDirector · Since at least Apr 9, 2026
Soad El GazaouiUntil Apr 9, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Carvolix.